The impact of stevioside supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a controlled clinical trial

Nearmeen M. Rashada, Mona A.E. Abdelsamadb, Atef M. Amerc, Mahmoud Z. Sitohyd, Mayada M. Mousaa

Departments of aInternal Medicine, bBiochemistry, cOrganic Chemistry, Faculty of Science, dDepartment of Biochemistry, Faculty of Agriculture, Zagazig University, Zagazig, Egypt

Correspondence to Nearmeen M. Rashad, MD, Department of Internal Medicine, Faculty of Medicine, Zagazig University, 44519, Zagazig, Egypt. Tel: +20 122 424 8642; e-mail: nrashad78@yahoo.com

Received 25 August 2018 Accepted 22 October 2018

The Egyptian Journal of Internal Medicine 2019, 31:22–30

Background

Stevia is a naturally occurring non-nutritive sweetener that has been reported as sugar substitutes for diabetic patients. We aimed to assess the impact of stevia supplementation on glycemic control in patients with type 2 diabetes mellitus (T2DM). Also, we aimed to examine the association between stevia supplementation and anthropometric measures as well as lipid profile in both obese and diabetic patients.

Patients and methods

The controlled clinical trial included unrelated 150 participants; 40 patients with T2DM and 60 obese patients and 50 healthy controls. Obese patients were then subdivided into two subgroups according to their fasting blood sugar: nondiabetic (n=30) and 30 patients with T2DM. The participants received stevia (4 mg/kg/body weight) as an alternative to artificial sweetener for 24 weeks.

Results

Our results found that stevioside supplementation for diabetic patients increased the total caloric intake and decreased BMI, waist circumference, waist–hip ratio, and fat mass index, in the obese group. Our results have shown a significant increase of BMI, waist circumference, waist–hip ratio, and fat mass index after 24 weeks of stevia supplementation. In the diabetic group, stevioside for 24 weeks improved the lipid profile and glycemic control, fasting plasma glucose, 2-h plasma glucose, fasting serum insulin, homeostasis model assessment of insulin resistance and hemoglobin A1c (HbA1c), as well as total cholesterol, triglycerides, low density lipoprotein-cholesterol, and high density lipoprotein-cholesterol in all studied intervention groups. Logistic regression test revealed that among clinical and laboratory waist circumference, fasting plasma glucose and HbA1c were independent predictors of response to stevioside.

Conclusion

Stevioside supplementations for 24 weeks improved cardiometabolic risk in diabetic patients. However, in the obese group, stevioside supplementations increased body weight.

Keywords:

obesity, randomized controlled trial, stevioside, type 2 diabetes

Introduction

The prevalence of obesity in Egypt has increased at an alarming rate during the last three decades affecting 22% of adult men and 48% of adult women [1]. It is associated with several comorbidities including hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), coronary heart disease, stroke, osteoarthritis, sleep apnea, and respiratory problems, as well as some types of cancers [2,3].

Type 2 diabetes is a metabolic disorder characterized by hyperglycemia, insulin resistance, and β-cell dysfunction. Its prevalence is increasing at an alarming rate worldwide [4–7]. Recent studies have explained the role of lifestyle, in particular daily diet in achieving glycemic target in patients with T2DM [7,8].

As a matter of fact, the consumption of a high sugar/high fat diet is one of the contributing factors attributed to the increase in obesity [9]. Increasing evidence points to critical roles of consumption of non-nutritive sweeteners (NNS) as an alternative to sugar intake [10]. There are eight Food Drug Administration (FDA)-approved NNS: sucralose, aspartame, saccharin, acesulfame-K, neotame, and advantame. Even more importantly, naturally derived NNS, steviol glycosides, and Luo Han Guo extract are generally recognized as safe and endorsed for use in

© 2019 The Egyptian Journal of Internal Medicine | Published by Wolters Kluwer - Medknow DOI: 10.4103/ejim.ejim_68_18
food by the US FDA and the European Food Safety Authority [11].

Stevia, the common name for the naturally derived NNS, steviol glycosides is an extract from the leaves of Stevia rebaudiana Bertoni. Stevia is a natural, sweet-tasting calorie-free botanical that may also be used as a sugar substitute or as an alternative to artificial sweeteners. There was scattered evidence that stevia improves glycemic control in diabetic patients and increases insulin levels [12], which suggest that it may have a role in food intake regulation. In experimental studies, stevia has been found to increase insulin sensitivity [13].

Regarding the safety of stevia consumption, evidence suggested that there were no negative side effects reported. Furthermore, stevia is inexpensive and available to most consumers; thus, it has the potential to be widely used and may assist individuals in regulating their weight if it has a positive effect on caloric substitution [14].

The pandemic of obesity represents a major public health concern, as this disorder is associated with an increased risk of medical comorbidities contributing to a significant rise in mortality. Despite a wide range of research being conducted, till now the treatment of obesity is still suboptimal. To our knowledge, no study to date in our region especially our country, Egypt evaluated the impact stevia supplementation on health and disease. Thus the aim of our study was to assess the impact of stevia supplementation on glycemic control in patients with T2DM. Also, we aimed to examine the association between stevia supplementation and anthropometric measures as well as lipid profile in both obese and diabetic patients.

**Patients and methods**

The controlled clinical trial included unrelated 150 participants: 40 patients with T2DM and 60 obese patients (BMI ≥ 30). The patients were recruited from the Diabetes and Endocrinology Outpatient Clinic of Internal Medicine Department of Zagazig University Hospitals. Obese patients were then subdivided into two subgroups according to the American Diabetes Association [15]: nondiabetic (n=30) and 30 patients with T2DM, in addition to 50 healthy controls who were matched to case groups as regards sex, age, and ethnicity. The participants received stevia (4 mg/kg/body weight) as an alternative to an artificial sweetener for 24 weeks.

At the beginning, the protocol and the aim of study were fully explained to the participants and written informed consent was obtained from each volunteer. The Ethics Committee of Faculty of Medicine, Zagazig University approved our study protocol. Any subjects with a history of cardiovascular disease and stroke, liver, renal disease, and chronic inflammatory or thyroid disease were excluded from the study. Also, all participants were not allowed to be vegetarians, vegans, or smoker. None of the participants had a history of abdominal surgery that could have an impact on abdominal fat distribution, as well as participating in a dietary or exercise programs during the preceding 6 months. The participants were also excluded if they had a diagnosable eating disorder or were disliking of or allergy to stevia, or were taking any medications or dietary supplements that could influence weight, appetite, hunger, or satiety. Acceptance of the supplements was investigated via weekly phone calls. During these calls possible problems such as supplement intolerance and medication use, possibly changes in food consumption, getting a new disease, or a change in physical activity was followed and if this situation occurred, the patient were excluded. Body weight was measured with light clothing but no shoes on a digital balance (with 0.1 kg sensitivity).

Height was assessed by using a stadiometer that measured to the nearest 0.1 cm. BMI was estimated as the ratio of body weight to height squared and expressed as kg/m². Waist circumference (with 0.1 cm sensitivity) was measured at the minimum circumference between the iliac crest and the last rib cage at the end of exhalation. The hip circumference was measured using tape as the maximal circumference over the hip and waist-to-hip ratio (WHR) was calculated. The participants were asked to maintain their normal physical activity during the study.

At baseline and at the end point of the 6-month study, anthropometrical measurements were estimated and blood samples were collected for biochemical analyses.

**Nutrition education intervention**

The nutrition intervention was designed based on macronutrient and micronutrient requirements; three 45–60 min training sessions were conducted at the beginning of the intervention. The described diet was based on the American Diabetes Association guidelines. A total energy of about 1600–200 kcal/day was calculated according to the Harris–Benedict equations revised by Mifflin et al. [15] \( \text{men BMR} = (10 \times \text{weight in kg}) + (6.25 \times \text{height in cm}) - (5 \times \text{age in} \)
years) + 5] and [women BMR = (10 × weight in kg) + (6.25 × height in cm) – (5 × age in years) – 161].

The diet including six meals per day, a macronutrient distribution of 50% total caloric value from carbohydrates, 20% proteins and 30% lipids, healthy fatty acids 30%, and a cholesterol consumption lower than 300 mg/day.

Blood sampling
Blood samples were drawn from all subjects after an overnight fast and were divided into three portions: 1 ml of whole blood was collected into evacuated tubes containing EDTA, for hemoglobin A1c (HbA1c) and 1 ml of whole blood was collected into evacuated tubes containing potassium oxalate and sodium fluoride (2:1) for fasting blood glucose. Serum was separated immediately from the remaining part of the sample and stored at −20°C until analysis.

Biochemical analysis
We measured fasting plasma glucose (FPG) levels using the glucose oxidase method (Spinreact, Girona, Spain). Total cholesterol, high density lipoprotein-cholesterol (HDL-C), and triglycerides levels were measured by routine enzymatic methods (Spinreact). The low density lipoprotein-cholesterol (LDL-C) level was calculated using the Friedewald formula [16].

Immunochemical assays
Fasting serum insulin concentrations were measured using the high-sensitivity-linked immunosorbent assay kit provided by Biosource Europe SA (Nivelles, Belgium). A homeostasis model assessment of insulin resistance (HOMA-IR) was calculated.

Dual-energy X-ray absorptiometry
The accurate and precise values of body composition parameters were estimated from dual-energy X-ray absorptiometry scan of the total body. They included fat mass (FM) and fat-free mass (FFM). Additionally, we calculated the fat mass index (FMI); fat mass/square height, and fat-free mass index (FFMI); fat-free mass /square height (kg/m²), was calculated.

Statistical analysis
Statistical analyses were performed using the statistical package for the social sciences for Windows (version 21.0; SPSS Inc., Chicago, Illinois, USA). Data were expressed using descriptive statistic (mean±SD) and were analyzed using t-test. Logistic regression analysis was done to evaluate the association of sativoside supplementation with clinical, anthropometric, and biochemical parameters of the studied groups. We considered P to be significant at less than 0.05 with a 95% confidence interval.

Results
Clinical, anthropometric, and laboratory characteristics of the studied groups at baseline
Clinical, anthropometric, and laboratory characteristics of the studied groups at baseline as shown in Table 1. In the intervention group, we found significant higher levels of body composition parameters: BMI, waist circumference, WHR, FM, FFM, FMI%, and FFMI%. Also, the levels of triglycerides, LDL-C, FPG, fasting serum insulin, HbA1c (%), and HOMA-IR were significantly higher in the intervention group compared with the control group. On the other hand, there were significant lower values

| Variables                        | Control group mean±SD | Intervention group mean±SD | P   |
|----------------------------------|-----------------------|-----------------------------|-----|
| Age (years)                      | 39.34±6.4             | 40.56±6.18                  | 0.467|
| Systolic blood pressure (mmHg)   | 122.44±6.68           | 126.7±17.58                 | 0.340|
| Diastolic blood pressure (mmHg)  | 78.14±4.68            | 79.47±9.361                 | 0.610|
| Waist circumference (mm)         | 99.9±4.698            | 121.77±19.639               | <0.001*|
| BMI (kg/m²)                      | 24.47±0.867           | 34.51±8.73                  | <0.001*|
| Waist/hip ratio                  | 0.99±0.046            | 1.21±0.196                  | <0.001*|
| FM                               | 13.44±1.031           | 18.03±3.831                 | <0.001*|
| FMI%                             | 4.89±0.17346          | 6.9±1.746                   | <0.001*|
| FFM                              | 53.74±4.125           | 72.14±14.9                  | <0.001*|
| FFMI%                            | 19.58±0.693           | 27.61±6.98                  | <0.001*|
| Total cholesterol (mg/dl)        | 183.73±3.75           | 193.68±32.54                | 0.260|
| Triglycerides (mg/dl)            | 114.1±1.406           | 135.71±31.4                 | <0.05*|
| LDL cholesterol (mg/dl)          | 85.88±0.187           | 103.4±35.2                  | 0.071|
| HDL cholesterol (mg/dl)          | 55.11±3.281           | 41.72±14.344                | <0.01*|
| Fasting plasma glucose (mg/dl)   | 87.11±3.281           | 98.21±19.17                 | <0.001*|
| HbA1c (%)                        | 5.09±0.150            | 7.24±2.194                  | <0.001*|
| 2-h blood glucose (mg/dl)        | 109.8±3.45            | 158.8±19.67                 | <0.001*|
| HOMA-IR                          | 1.13±0.098            | 2.64±1.23                   | <0.001*|
| Fasting serum insulin (μIU/ml)   | 7.48±0.141            | 10.43±2.65                  | <0.001*|

FFM, fat-free mass; FFM, fat-free mass index; FM, fat mass; FMI, fat mass index; HDL, high density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low density lipoprotein. *P<0.05.
of HDL in the case group compared with the control group \((P<0.05)\).

**Macronutrient and micronutrient intakes before and after 24 week’s intervention by stevioside supplementation**

In the control group, there were nonsignificant changes regarding energy (kcal/day), total carbohydrate (g), total protein (g), and total fat (g) in diet intakes before and after 24 week’s intervention by stevioside supplementation. However, in the intervention group, there were significantly higher values of total energy (kcal/day), total carbohydrate (g), total protein (g), and total fat (g) in diet after 24 week’s intervention by stevioside supplementation compared with the diet regimen before the intervention (Fig. 1).

**The impact of stevioside supplementations on clinical and anthropometric parameters**

We tested the role of stevioside supplementations an alternative to sugar sweetener in intervention groups. The case groups were subclassified into obese, obese diabetic, and diabetic groups. In the obese group, our results showed significantly increased body composition parameters by using stevia as NNS; the parameters were: BMI, waist circumference, and WHR. Additionally, FM, FMI, FFM, and FFMI were significantly increased after stevia supplementation (Table 2).

Among the obese diabetic group, there were significant differences between baseline and after 24 weeks of stevioside supplementation as regards waist circumference, BMI, and FMI, FFM, and FFMI. As regards the diabetic group, supplementation with stevioside for 24 weeks had significant effects on BMI, waist circumference, WHR, and FMI (Table 2).

**The impact of stevioside supplementations on the biochemical variable of the studied case group**

The impact of stevioside supplementations on the biochemical variable of the studied case group as shown in Table 3. Regarding the diabetic group, supplementation with stevioside for 24 weeks had significant improvement on FPG (128.1±28.1 vs. 141.7±34.6), 2-h plasma glucose (198.2±53.02 vs. 251.5±59.2), HOMA-IR (5.8±2.2), HbA1c (8.3±1.1 vs. 7.9±0.9), and total cholesterol (158.9±24.5 vs. 167.1±30.9), LDL-C (100.91±39.53 vs. 125.8±33.6), and HDL-C (36.2±8.267 vs. 34.79±11.56; Fig. 2).

In the obese group, our results revealed significantly improved lipid profile: total cholesterol (188.2±25.9 vs. 210.5±47.4), triglycerides (144.7±30.6 vs. 150.9±35.9), LDL-C (102.9±31.1 vs. 121.9±47.6), and HDL-C (36.25±17.09 vs. 33.6±8.44). Furthermore, fasting serum insulin was significantly decreased after stevia supplementation (Fig. 3).

In the obese diabetic group, stevioside supplementation for 24 weeks led to significant improvement of glycemic control tests; FPG (183.2±53 vs. 196.5±59.2), 2-h plasma glucose (183.1±28.1 vs. 293.7±34.64) HOMA-IR (3.2±0.9 vs. 3.7±1.28) and HbA1c (8.56±0.9 vs. 9.7±1.1). Interestingly, lipid profile parameters also improved after stevioside supplementation for 24 weeks of these parameters: total cholesterol, LDL-C, and HDL-C (Figs 2 and 3).
Assessment of stevioside supplementation as non-nutritive sweeteners in the improvement of anthropometric and biochemical variable of the studied group

Logistic regression analysis was performed to detect the main predictors associated with stevioside supplementation in the diabetic group. Our findings have shown that among clinical and laboratory waist circumference, FPG and HbA1c were independent positive predictors of response to stevioside supplementation with odds ratios of 1.047, 1.026, and 0.360, respectively (\(P<0.05\), \(<0.05\), and \(<0.01\), respectively; Table 3).

**Discussion**

Obesity is a complex, multifactorial, and largely preventable disease, affecting, along with overweight, over a third of the world’s population today [17]. Over the past decade, a close association between obesity and diabetes has become increasingly clear. Childhood obesity results in the same conditions,
with premature onset, or with greater likelihood in the adulthood [18].

It is also well established that the consumption of foods and beverages containing NNS has dramatically increased over the past few decades [19]. There is controversy regarding the consumption of NNS; one of the most popular NNS is stevia. Stevia was recently approved for use as a sweetener by the Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives (Joint Food and Agriculture Organization/World Health Expert Committee on Food Additives, 2005) [20] and by the FDA. Stevia is a naturally sourced, zero-calorie
sweetener that has been used as a natural sugar substitute and flavoring ingredient for 100’s of years. The acceptable daily intake is 4 mg/kg of body weight per day for steviol equivalents [19].

Low-calorie artificial sweeteners can help to decrease blood glucose levels and can inhibit metabolic disorders. The effects of artificial sweeteners on obesity and related metabolic disorders remain controversial. We in this study attempted to pierce out the impact of stevia supplementation on glycemic control, and lipid profile in patients with type 2 diabetes. Also, we aimed to examine the association between stevia supplementation and anthropometric measures in both obese and diabetic patients.

It would be of considerable practical issues to test the metabolic effects of NNS. Among NNS, we tested the role of stevioside supplementations as an alternative to sugar sweetener in obese, obese diabetic, and diabetic patients.

The interesting result of our study was the effect of stevioside supplementation for 24 weeks on anthropometric measures. According to our results, stevioside supplementation for diabetic patients increased total caloric intake and decreased BMI, waist circumference, WHR, and FMI. Even more interestingly, in the obese group, our results have shown significant increase of BMI, waist circumference, WHR, and FMI after 24 weeks of stevia supplementation.

There is no clear evidence that NNS augment appetite by activating cephalic phase responses, altering osmotic balance, or enhancing food palatability. Indeed, there is emerging evidence that selected NNS may stimulate the release of satiety hormones, although the link between these hormones and energy intake in free-living individuals is also open to debate. With respect to energy intake, there is no substantive evidence that an inherent liking for sweetness or NNS activation of reward systems is problematic.

In a human clinical intervention study conducted by Parker and his colleagues they found that the participants who used NNS were significantly more likely to gain weight than were nonusers. However, the weight gain was less than 2 lb (≈0.9 kg) between users and nonusers [20].

Similar results were obtained by previous animal studies. Researchers have suggested that the intake of NNSs may promote weight gain, either by increasing energy intake [21], or by decreasing energy expenditure [22–26].

Previous researches reported that premeal consumption of high calories leads to reduced food intake, a process known as caloric compensation [27]. Thus, it is possible that the controls fed on high-calorie sugars were subjected to caloric compensation and consumed less food and this led to reduced weight gain when compared with the treated groups.

Similarly, Abo Elnaga et al. [27] observed administration of stevia sweetener at doses of 25 mg/kg, body weight decreased feed intake as compared with the control group. There is scattered evidence that found decreased rat weight after supplementation of stevia. They explained that these changes in body weight of rats could be due to the absence of quick glucose-releasing source or due to decrease in the caloric intake by rats [28,29].

Stevia is inexpensive and available to most consumers; thus, it has the potential to be widely used and may assist individuals in regulating their weight if it has a positive effect on caloric substitution. However, no study to date has examined the effect stevia has on food intake and satiety levels.

The main finding of the present study is that there were significant improvement in lipid profile; total cholesterol, triglycerides, LDL-C, and HDL-C as well as fasting serum insulin in all studied intervention groups.

Similar to our results, the experimental study of Abo Elnaga et al. [27] observed that the groups of rats treated with stevia sweetener had improvement in lipid profile levels compared with the negative or positive control group.

Our finding adds to the growing body of evidence implicating the need for stevioside supplementation for lean and obese patients with T2DM. In both groups, stevioside supplementation for 24 weeks led to significant improvement of glycemic control tests: FPG, 2-h plasma glucose, HOMA-IR, and HbA1c.

Our findings are in concordance with Anton et al. [30], who conducted their study to evaluate the effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose as well as insulin levels and they observed that consumption of stevia in preloads significantly lowered postprandial insulin levels compared with both aspartame and sucrose, as well
as postprandial glucose levels compared with sucrose. These effects on postprandial glucose levels are likely due in large part to the lower caloric and carbohydrate intake of stevia supplementation compared with other artificial sweeteners.

In agreement with our results, Viswanathan et al. [31] found that stevia may be helpful in managing postprandial hyperglycemia, insulin resistance, and T2DM.

Our findings are in concordance with Saltiel et al. [32] which suggest that the presence of pharmacological concentrations of sucralose and stevioside on the basolateral membrane may increase GLP–1 secretion. However, given the high concentrations needed to stimulate secretion, this finding is probably of limited clinical relevance.

Similar results confirmed by the Romo–Romo et al. [33] results revealed stevia consumption as one of the natural NNS that led to lower glucose and insulin concentrations compared with sucrose.

As a consequence of our studies, we further evaluated our results by the logistic regression test which revealed that among clinical and laboratory waist circumference, FPG, and HbA1c were independent predictors of response to stevioside.

Anton et al. [30] observed that the participants did not compensate by eating more at either their lunch or dinner meal and reported similar levels of satiety when they consumed lower calorie preloads containing stevia or aspartame than when they consumed higher-calorie preloads containing sucrose.

Tey et al. [34] suggested that the consumption of NNS is not encouraged, but they could be considered a useful tool in the nutritional treatment of certain metabolic diseases as sugar substitutes as long as the quantity consumed is within the acceptable daily intake and without compensation by ingesting other energy-rich foods.

Paula Neto et al. [35] detected that sweeteners, which are freely used by obese and diabetic patients had hazards effect on the gut microbiota, which contributed to the development of insulin resistance and weight gain.

**Conclusion**

Stevioside supplementations to T2DM decreased anthropometric measures and cardiometabolic risks. Notwithstanding, in obese patients the consumption of stevia as NNS increased body composition values; thus, these additives should not be considered as safe and must have their use controlled and labeled with regard to the possible undesirable effects.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Badran M, Laher I. Obesity in Arabic-speaking countries. J Obes 2011; 2011:866430–686439.
2. Frühbeck G. Obesity: screening for the evident in obesity. Nat Rev Endocrinol 2012; 8:570–572.
3. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384:766–781.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32(Suppl 1):S62–S67.
5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4–14.
6. Gubitosi-Klug RA, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care 2014; 37:44–49.
7. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 2014; 383:1999–2007.
8. American Diabetes Association. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. Diabetes Care 2015; 38 (Suppl):20–30.
9. Barquera S, Hernandez-Barrera L, Tolentino ML, Espinosa J, Ng SW, Rivera JA, et al. Energy intake from beverages is increasing among Mexican adolescents and adults. J Nutr 2008; 138:2454–2461.
10. Shankar P, Ahuja S, Sirimak K. Non-nutritive sweeteners: review and update. Nutrition 2013; 29:1293–1299.
11. Food US and Drug Administration. Additional information about high-intensity sweeteners permitted for use in food in the United States 2015 [updated 05/25/2015; cited 2016 02/01/2016]. Available: http://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397725.htm.
12. Curi R, Alvarez M, Bazotte RB, Botlon LM, Godoy JL, Bracht A. Effect of Stevia rebaudiana on glucose tolerance in normal adult humans. Braz J Med Biol Res 1986; 19:771–774.
13. Chang JC, Wu MC, Liu IM, Cheng JT. Increase of insulin sensitivity by stevioside in fructose-rich chow-fed rats. Horm Metab Res 2005; 37:610–616.
14. Barriocanal LA, Palacios M, Benitez O, Benitez S, Jimenez JT, Jimenez N, et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypertensive individuals and in type 1 and type 2 diabetics. Regul Toxicol Pharmacol 2008; 51:37–41.
15. Mifflin MD, St Jeor ST, Hill ST, Lurn LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990; 51:241–247.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.
17. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012; 10:22.
18. Hu FB, Obesity epidemiology. Oxford New York: Oxford University Press; 2008. p. 488.
19. Mattes RD, Popkin BM. Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms. Am J Clin Nutr 2009; 89:1–14.
20 Parker DR, Gonzalez S, Derby CA, Gans KM, Lasater TM, Carleton RA. Dietary factors in relation to weight change among men and women from two southeastern New England communities. Int J Obes Relat Metab Disord 1997; 21:103–109.

21 Porikos KP, Koopmans HS. The effect of non-nutritive sweeteners on body weight in rats. Appetite 1988; 11(Suppl 1):12–15.

22 Swithers SE, Baker CR, Davidson TL. General and persistent effects of high-intensity sweeteners on body weight gain and caloric compensation in rats. Behav Neurosci 2009; 123:772–780.

23 Swithers SE, Davidson TL. A role for sweet taste: calorie predictive relations in energy regulation by rats. Behav Neurosci 2008; 122:161–173.

24 Swithers SE, Laboy AF, Clark K, Cooper S, Davidson TL. Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats. Behav Brain Res 2012; 233:1–14.

25 Swithers SE, Sample CH, Davidson TL. Adverse effects of high-intensity sweeteners on energy intake and weight control in male and obesity-prone female rats. Behav Neurosci 2013; 127:262–274.

26 Feijó FM, Ballard CR, Foletto KC, Batista BAM, Neves AM, Ribeiro M, et al. Saccharin and aspartame, compared with sucrose, induce greater weight gain in adult wistar rats, at similar total caloric intake levels. Appetite 2013; 60:203–207.

27 Abo Elnaga IE, Massoud MI, Yousef MI, Mohamed HHA. Effect of stevia sweetener consumption as non-caloric sweetening on body weight gain and biochemical’s parameters in overweight female rats. Ann Agric Sci 2016; 61:155–163.

28 Gregersen S, Jeppesen PB, Holst JJ, Hermansen K. Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism 2004; 53:73–76.

29 Wiebe N, Padwal R, Field C, Marks S, Jacobs R, Tonelli M. A systematic review on the effect of sweeteners on glycemic response and clinically relevant outcomes. BMC Med 2011; 9:123–141.

30 Anton SD, Martin CK, Han H, Coulon S, Cefalu WT, Geiselman P, Williamson DA. Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. Appetite 2010; 55:37–43.

31 Viswanathan V, Clementina M, Nair BM, Satyavani K. Risk of future diabetes is as high with abnormal intermediate post-glucose response as with impaired glucose tolerance. J Assoc Physicians India 2007; 55:833–837.

32 Saltiel MY, Kuhre RE, Christiansen CB, Eliasen R, Conde-Friboes KW, Rosenkilde MM, Holst JJ. Sweet taste receptor activation in the gut is of limited importance for glucose-stimulated GLP-1 and GIP secretion. Nutrients 2017; 9:418.

33 Romo-Romo A, Aguilar-Salinas CA, Brito-Córdova GX, Gómez Díaz RA, Vilchis Valentín D, Almeda-Valdes P. Effects of the non-nutritive sweeteners on glucose metabolism and appetite regulating hormones: systematic review of observational prospective studies and clinical trials. PLoS One 2016; 11:0161264.

34 Tey SL, Salleh NB, Henry J, Forde CG. Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake. Int J Obes (Lond) 2017; 41:450–457.

35 Paula Neto HA, Ausina P, Gomez LS, Leandro JGB, Zancan P, Sola-Penne M. Effects of food additives on immune cells as contributors to body weight gain and immune-mediated metabolic dysregulation. Front Immunol 2017; 8:1478.